Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
20 sept. 2021 16h05 HE
|
Verrica Pharmaceuticals Inc.
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer No Clinical, Safety or CMC Issues Specific to...
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
10 août 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
09 juil. 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
28 mai 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 – WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”)...
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference
26 mai 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
12 mai 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results
07 mai 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised...
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
06 avr. 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
29 mars 2021 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Pricing of Public Offering of Common Stock
22 mars 2021 21h31 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...